MorphoSys (MOR) News Today $18.96 0.00 (0.00%) As of 08/5/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comNovartis shutters MorphoSys sites, lays off staffDecember 19, 2024 | finance.yahoo.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19, 2024 | reuters.comNovartis raises mid-term sales guidanceNovember 21, 2024 | seekingalpha.comNovartis: launch of Morphosys drug by could be 2027 or laterNovember 21, 2024 | reuters.comIdiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).November 14, 2024 | theglobeandmail.comTango stock plunges 28% amid pipeline updates, Q3 earnings reportNovember 6, 2024 | msn.comMyrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma ReeveOctober 16, 2024 | finance.yahoo.comBiogen: Felzartamab Receives Breakthrough Therapy Designation - Quick FactsOctober 9, 2024 | markets.businessinsider.comNovartis Stock: Resilient Performance Amid Market VolatilityOctober 8, 2024 | finanznachrichten.deEnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategySeptember 26, 2024 | tmcnet.comNovartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerSeptember 17, 2024 | finanznachrichten.deMorphoSys AG: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | finanznachrichten.deEQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | markets.businessinsider.comMorphoSys (MOR) Set to Announce Earnings on ThursdayAugust 22, 2024 | marketbeat.comMORF Apr 2025 62.500 call(CONTR (MORF250417C00062500)August 18, 2024 | finance.yahoo.comIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaAugust 15, 2024 | stockhouse.comMorphoSys AG (MORD.XC)August 13, 2024 | uk.finance.yahoo.comMorphoSys AG (1MOR.MI)August 12, 2024 | sg.finance.yahoo.comRoyalty Pharma Reports Second Quarter 2024 ResultsAugust 8, 2024 | markets.businessinsider.comXencor Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | stockhouse.comEuropean Equities Traded in the US as American Depositary Receipts Plunge in Monday TradingAugust 5, 2024 | msn.comLeerink Partnrs Analysts Boost Earnings Estimates for MorphoSys AG (NASDAQ:MOR)July 29, 2024 | marketbeat.comEVPassport Announces Opening of East Coast Headquarters in Boston and Key Executive Appointments Amidst Rapid GrowthJuly 25, 2024 | tmcnet.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MORJuly 16, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MORJuly 15, 2024 | prnewswire.comSusquehanna International Securities Ltd. Cuts Position in MorphoSys AG (NASDAQ:MOR)July 14, 2024 | marketbeat.comMorphoSys: Novartis Deal Is All But DoneJuly 8, 2024 | seekingalpha.comHennion & Walsh Asset Management Inc. Has $2.12 Million Position in MorphoSys AG (NASDAQ:MOR)June 29, 2024 | marketbeat.comShort Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 65.0%June 27, 2024 | marketbeat.comMOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to ShareholdersJune 20, 2024 | businesswire.comMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority ShareholdersJune 20, 2024 | businesswire.comOpaleye Management Inc. Has $1.44 Million Stock Holdings in MorphoSys AG (NASDAQ:MOR)June 15, 2024 | marketbeat.com4,234,685 Shares in MorphoSys AG (NASDAQ:MOR) Bought by Kynam Capital Management LPJune 10, 2024 | marketbeat.comMorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from BrokeragesJune 9, 2024 | marketbeat.comMorphoSys AG (NASDAQ:MOR) Shares Purchased by TD Asset Management IncJune 7, 2024 | marketbeat.comMonoclonal Antibody May Benefit Patients With Kidney Transplant RejectionMay 28, 2024 | msn.comNovartis releases Phase III data on its investigational oral therapy to treat chronic kidney diseaseMay 27, 2024 | msn.comMorphoSys (MOR) Scheduled to Post Earnings on MondayMay 26, 2024 | marketbeat.comNovartis Pharma AG: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | finanznachrichten.deNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | finance.yahoo.comNovartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash DealMay 16, 2024 | markets.businessinsider.comNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | globenewswire.comMorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2024 | marketbeat.comMorphoSys (NASDAQ:MOR) Sets New 1-Year High at $18.38May 14, 2024 | marketbeat.comShort Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 18.3%May 13, 2024 | marketbeat.comMorphoSys (ETR:MOR) shareholders have earned a 228% return over the last yearMay 10, 2024 | finance.yahoo.comMorphoSys AG (MOR2.DU)May 6, 2024 | finance.yahoo.com Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address MOR Media Mentions By Week MOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOR News Sentiment▼0.000.42▲Average Medical News Sentiment MOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOR Articles This Week▼00▲MOR Articles Average Week Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VTRS News Today ASND News Today BBIO News Today VRNA News Today BPMC News Today LEGN News Today ROIV News Today RGC News Today ELAN News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MOR) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
